Early Access — free while we kick the tires
EdgarHawk

Kim Helen Susan

Director

Director 10% Owner
1 filing analyzed · 1 company · Latest 2026-01-12

Companies

Company Buys Sells Direction
Aktis Oncology, Inc. AKTS 4 0 Net buying

Activity

January 2026
2026-01-12 Aktis Oncology, Inc. AKTS
high
Buy
835,000 shares
$15,030,000
Significance 8/10

Director Kim Helen Susan bought 835,000 shares for $15,030,000.00 at $18.00; AKTS stock now trades at $21.75 post-IPO with 5 other insiders buying within 14 days.

Director Kim Helen Susan purchased 835,000 shares (835.0K shares) across 2 separate transactions for a total of $15,030,000.00 at a blended average price of $18.00 on 2026-01-12. The transaction occurred 2 trading days after AKTS listing, with current trading at $21.75. This large-scale purchase is part of a broader insider cluster: 5 other insiders also bought within the past 14 days, establishing a coordinated multi-insider accumulation pattern in the early post-IPO window. The filing involves a derivative-conversion transaction; the director's total economic position extends beyond the Table I shares shown and should not be assessed as a complete position snapshot. Investors should note the synchronized buying momentum across multiple insiders during the earliest trading window.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access